In the past decade, the therapeutic arsenal for multiple sclerosis has expanded greatly.
Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions …

Introduction We systematically reviewed adverse events (AEs) for ocrelizumab for multiple
sclerosis (MS). Areas covered We searched Medline, Embase, Web of Science, and …

Introduction The portfolio of multiple sclerosis (MS) disease modifying treatments (DMTs)
has significantly expanded over the past two decades. Given the lifelong use of MS …

Introduction In recent years, many treatment options have become available for relapsing
remitting MS. Randomized clinical trials and real-world studies are complementary sources …

Available data support the widespread use of therapies targeting B cells in MS. Whether
novel approaches targeting CD19 or BTK will have advantages compared to anti-CD20 …

Monoclonal antibodies have become a mainstay of treatment for many inflammatory
diseases and malignancies. Multiple sclerosis is a chronic inflammatory, demyelinating, and …

In the past decade, the therapeutic arsenal for multiple sclerosis has expanded greatly.
Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions …